Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 30
  1. Apr 22, 2026 · 07:00 · GREY · Routine −

    Grey Matters Health Raises Capital at Discount to Fund US Clinic Expansion Amidst Dilution Concerns

    Grey Matters Announces Private Placement

    01
  2. Apr 22, 2026 · 04:00 · RKV · Routine +

    AI-Driven Oncology Pipeline Validates Preclinical Efficacy

    Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

    02
  3. Apr 22, 2026 · 03:02 · PREV · Routine −

    PreveCeutical Raises Cash at Discount Amidst Dilution Concerns

    PreveCeutical Announces Non-Brokered Private Placement

    03
  4. Apr 21, 2026 · 18:00 · ONCO · Routine +

    Onco-Innovations Advances CMC Milestones Amidst Severe Valuation Compression

    Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program

    04
  5. Apr 21, 2026 · 16:49 · TELY · Material +

    N/A

    TelyRx Announces Year-End 2025 Financial Results

    05
  6. Apr 21, 2026 · 16:30 · FRX · Routine +

    Fennec Pharmaceuticals

    Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

    06
  7. Apr 21, 2026 · 14:10 · IZO · Routine −

    Izotropic Settles Debt with Equity Amidst Africa Expansion Push

    Izotropic Announces Debt Settlement

    07
  8. Apr 21, 2026 · 08:01 · PHRM · Routine +

    Strategic Alignment with Federal Psychedelic Mandate

    PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

    08
  9. Apr 21, 2026 · 08:00 · AIDR · Routine +

    Strategic Expansion

    Rocket Doctor Further Expands Maryland Access by ~ 250,000 Additional Members Through New In-Network Agreement

    09
  10. Apr 21, 2026 · 07:30 · MDNA · Routine +

    Preclinical Validation Meets Liquidity Crunch

    Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

    10
  11. Apr 21, 2026 · 07:30 · BCT · Routine +

    BriaCell Therapeutics Corp

    BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models

    11
  12. Apr 21, 2026 · 07:15 · PINK · Material −

    Perimeter Medical Imaging AI Secures Lifeline Financing at Discount to Market Price Amidst Cash Burn Concerns

    Perimeter Medical Imaging AI Announces LIFE Financing and Concurrent Private Placement

    12
  13. Apr 21, 2026 · 07:01 · WELL · Routine +

    Margin Expansion Validates Operational Leverage Amidst U.S. Asset Divestiture Uncertainty

    WELL Health Reports Record Canadian Patient Visits and Primary Care Margin Expansion in Q1-2026

    13
  14. Apr 21, 2026 · 07:00 · EPRX · Routine +

    Eupraxia Durability Data Validates Lead Candidate, Yet Phase 2b Timing Shifts to Q4

    Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

    14
← Newer Older →